The Aurora Kinase Inhibitor TAK901 Inhibits Glioblastoma Growth by Blocking SREBP1-Mediated Lipid Metabolism
Open Access
Abstract
Glioblastoma (GBM) is the most common and lethal malignant primary brain tumor. The standard treatment for GBM including surgical resection followed by radiation therapy and adjuvant chemotherapy with temozolomide remains unsatisfactory. In this study, we investigated the effects of the Aurora kinase inhibitor, TAK901, in GBM both in vitro and in vivo, and explored its key downstream targets. The effects of TAK901 were investigated using cell viability, cell apoptosis, live/dead, cell cycle, Transwell, 3D cell invasion, neuro-sphere, and self-renewal assays. Mechanistic studies were conducted using RNA-seq, lipid measurements, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Western blotting. The in vivo efficacy of TAK901 was validated using orthotopic xenograft GBM mouse models. In both GBM cells and GSCs, TAK901 remarkably reduced cell viability, self-renewal, migration and invasion and induced apoptosis and cell cycle arrest. Treatment with TAK901 considerably inhibited GBM growth in vivo. RNA-seq and RT-qPCR analyses showed that TAK901 downregulated the expression and activation of SREBP1. Moreover, SREBP1 overexpression alleviated the TAK901-mediated suppression of cell viability and apoptosis in GBM cells. Our results provide evidence that TAK901 inhibits GBM growth by suppressing SREBP1-mediated lipid metabolism.Keywords
Funding Information
- National Natural Science Foundation of China (82273454, 82172834)
- Natural Science Foundation of Jiangsu Province (BK20181156)
- Natural Science Foundation of Hunan Province (2022JJ30946)
This publication has 50 references indexed in Scilit:
- Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growthCancer & Metabolism, 2013
- Cancer Cell Metabolism: One Hallmark, Many FacesCancer Discovery, 2012
- An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent PathwayCancer Discovery, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic TherapyScience Signaling, 2009
- Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteinsCurrent Opinion in Cell Biology, 2009
- The aurora kinase A regulates GSK-3β in gastric cancer cellsOncogene, 2008
- Targeting Cancer Stem Cells through L1CAM Suppresses Glioma GrowthCancer Research, 2008
- Protein Sensors for Membrane SterolsCell, 2006
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003